Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05785715 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT05785715 is a Phase 2 study that was terminated before completion, run by AbbVie. The registered enrollment target is 81 participants.
The verdict
NCT05785715, a Phase 2 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
Interventions
- DRUG NX-13 250mg
- DRUG NX-13 750mg
- DRUG NX-13 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05785715
The ClinicalTrials.gov registry entry for NCT05785715 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which NX-13 250mg is the first listed.
NCT05785715 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05785715 about?
NCT05785715 is a clinical study titled "Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis". Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
What is the current status of trial NCT05785715?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2023-04-24. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05785715?
The interventions under investigation include: NX-13 250mg (DRUG), NX-13 750mg (DRUG), NX-13 Placebo (DRUG).
Who is sponsoring clinical trial NCT05785715?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.